NASDAQ$APGE

Apogee Therapeutics Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$0.51

Previous: -$11.75+95.7%
Capital Expenditures

$0.00

No prior period
Free Cash Flow

-$19.9M

No prior period
Net Income

-$20.8M

Previous: -$19.7M-6.0%
Operating Income

-$24.3M

Previous: -$10.5M-131.3%
Gross Profit

$0.00

No prior period
Cash & Equivalents

$423M

Previous: $2.58M+16270.7%
Total Assets

$426M

No prior period
R&D Expense

$17.1M

No prior period
Stock-Based Comp

$1.51M

No prior period

Revenue & EPS history

Apogee · Revenue · Quarterly

$0

Q3 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 15 quarterly earnings reports · overlaid with Q3 2023

Historical avgQ3 2023

+5.6%

Avg return

Earnings day

+9.2%

Avg return

5 days after

+10.9%

Avg return

30 days after

53%

8 / 15 earnings

Positive

+59.8%

Q4 2023

Best reaction

-12.7%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025+1.2%+4.4%+20.3%
Q3 2025+3.8%+19.7%+39.0%
Q2 2025-2.2%+5.4%+5.9%
Q1 2025-0.0%-1.1%+9.4%
Q4 2024-0.2%+14.9%+20.3%
Q3 2024-12.7%-21.8%-26.7%
Q2 2024+9.7%+11.7%+25.0%
Q1 2023+1.5%-5.5%-16.7%
Q1 2024+1.5%-5.5%-16.7%
Q4 2023+59.8%+61.8%+41.4%
Q3 2023+12.8%+20.6%+45.9%
Q3 2022+12.8%+20.6%+45.9%
Q4 2022-1.1%+4.0%-9.6%
Q2 2022-1.1%+4.0%-9.6%
Q2 2023-1.1%+4.0%-9.6%
Q1 2022

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro